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Abstract 
Introduction: “One-off” systematic case finding for COPD using a respiratory screening questionnaire 
is more effective and cost-effective than routine care at identifying new cases. However, it is not known 
whether early diagnosis and treatment is beneficial in the longer term. We estimated the long-term cost-
effectiveness of a regular case-finding programme in primary care. 
Methods: A Markov decision-analytic model was developed to compare the cost-effectiveness of a 3-
yearly systematic case finding programme targeted to ever smokers aged >50 years with the current 
routine diagnostic process in UK primary care. Patient-level data on case-finding pathways was 
obtained from a large RCT. Information on the natural history of COPD and treatment effects was 
obtained from a linked COPD cohort, UK primary care database and published literature. The 
discounted lifetime cost per quality-adjusted life year (QALY) gained was calculated from a health 
service perspective. 
Results: The incremental cost-effectiveness ratio of systematic case finding versus current care was 
£16,596 per additional QALY gained, with a 78% probability of cost-effectiveness at a £20,000 per 
QALY willingness-to-pay threshold. The base case result was robust to multiple one-way sensitivity 
analyses. The main drivers were response rate to the initial screening questionnaire and attendance rate 
for the confirmatory spirometry test.  
Discussion: Regular systematic case-finding for COPD using a screening questionnaire in primary care 
is likely to be cost-effective in the long-term despite uncertainties in treatment effectiveness. Further 
knowledge of the natural history of case-found patients and the effectiveness of their management will 
improve confidence to implement such an approach. 
 
Key messages 
What is the key question? 
What is the long-term cost-effectiveness of undertaking a regular programme of case-finding and 
early detection of COPD? 
What is the bottom line? 
Health economic decision modelling found that systematic case-finding among ever-smokers aged 50 
and over on a 3-yearly basis is highly likely to be cost-effective compared with routine practice.  
Why read on? 
Currently, case-finding programmes for COPD are not being implemented internationally due to the 
lack of evidence on the long-term benefits and cost-effectiveness of early diagnosis, and this paper 
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presents the first analysis of the long-term cost-effectiveness of systematic case-finding for 
undiagnosed COPD 
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Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is one of the most common long-term conditions 
with significant public health impact, costing over £1.5 billion per annum to the UK NHS1, largely 
due to emergency hospital admissions among patients experiencing exacerbations and costs of 
maintenance medication2. Despite considerable health service use3 it is thought that perhaps half of all 
subjects with this disease still remain undiagnosed4. Smoking cessation interventions, 
pharmacotherapy and non-pharmacological approaches such as pulmonary rehabilitation and self-
management can reduce morbidity, particularly the frequency of exacerbations, and prolong the life of 
diagnosed COPD patients5-9. Observed benefits might be even greater if undiagnosed patients were 
found earlier and appropriate treatment commenced, although evidence to support this is currently 
limited10. 
A number of small uncontrolled studies of different approaches to identify patients with undiagnosed 
COPD from primary care and other settings have been undertaken11, but there are few appropriately 
designed trials to address this issue. We recently conducted the largest cluster randomised controlled 
trial (TargetCOPD)12 to evaluate two alternative systematic approaches to identify undiagnosed 
symptomatic patients compared with routine practice (no systematic case-finding). The systematic 
strategies consisted of opportunistic case-finding, where a respiratory screening questionnaire was 
administered when eligible patients attended their primary care practice for consultation, and an active 
approach, where patients were additionally invited by mail to complete the same questionnaire. In both 
cases, symptomatic patients were then invited for diagnostic spirometry. Over the one-year trial period, 
active case-finding was the most effective and cost-effective approach to identify new cases (OR=7.5 
[95%CI=4.80-11.55]; £333 per additional case detected) compared with routine practice.  
Although short-term clinical and cost-effectiveness of a single “one-off” programme of case-finding 
was demonstrated, this does not necessarily translate into future long-term benefits for a regular 
programme. Furthermore, the results of the economic analysis (cost per case detected) are not easily 
comparable with results from other health programmes13. In the absence of long-term trial data, model-
based economic evaluations are needed14. We report the results of a model-based economic evaluation 
of the long-term costs and benefits of a regular programme of systematic active case-finding over 
routine practice, using data from the TargetCOPD trial12, the linked Birmingham COPD cohort15, a 
large primary care database and the published literature. The model outcome is expressed in cost per 
quality-adjusted life year (QALY) gained, a measure where a cost-effectiveness decision threshold rule 
exists in the UK16.  
Methods 
Study design and intervention 
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A Markov decision model was built with TreeAgePro 2015 (TreeAge Software, Williamstown, MA, 
USA) to estimate the long-term cost-effectiveness of systematic active case-finding for COPD among 
ever-smokers without a prior diagnosis of COPD in primary care versus routine practice. A cost-utility 
analysis was undertaken, to calculate the cost per QALY gained from a health service perspective (the 
UK NHS).  
The model was based on the methods in our published case-finding trial, using data from the most 
effective strategy identified in the trial (“active” case finding) compared with routine care12 17. The 
population in the trial comprised ever smokers aged 40-79 years without a prior diagnosis of COPD. 
However, for this long-term model, we chose a starting cohort of those aged 50 years, as few patients 
were identified below this age in the trial12.  
For the active case-finding approach, eligible patients were identified through electronic health records 
using a standardised search and their records “flagged”. Flagged patients were offered a respiratory 
symptom screening questionnaire at any routine practice visit, and were also sent the questionnaire by 
mail with a reply-paid envelope with up to two reminders. Patients who reported relevant chronic 
respiratory symptoms on the questionnaire were invited for a confirmatory spirometry test to diagnose 
COPD according to UK criteria18. Routine practice was defined according to UK and international 
guidance19, which recommends spirometric confirmation of COPD among those over the age of 35 
years who have a risk factor (generally smoking) and who present with exertional breathlessness, 
chronic cough, regular sputum production, frequent winter ‘bronchitis’ or wheeze18. Case-finding was 
a one-off activity in the TargetCOPD trial, but in this study we have assumed that the intervention 
would be repeated every three years. 
Model structure 
Patients without a prior COPD diagnosis in each strategy moved between 14 mutually-exclusive health 
states over their lifetime (Figure 1). The health states were grouped into three broad disease categories: 
disease-free, undiagnosed disease, diagnosed disease, dead. Patients with no airflow obstruction, either 
with or without respiratory symptoms, were classified as “disease free”. Those with relevant respiratory 
symptoms and airflow obstruction were classified as either remaining undiagnosed or becoming 
diagnosed. A diagnosis required either a new health record of a COPD diagnosis through routine care 
or receiving a diagnosis through the case-finding programme18 20. COPD health states were defined 
according to the traditional GOLD severity classification with stages 1-4 based on airflow obstruction21 
in line with previous Markov models on the management of COPD22. However, the GOLD stage 4 
health state was not made available for undiagnosed patients as virtually no patients were newly 
identified as severe as GOLD stage 4 in previous case-finding studies11 12. The model had a time cycle 
of three months; short enough to capture important COPD-related events such as exacerbations23. The 
time horizon was 50 years assuming a maximum age of 100 years. 
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The base case starting cohort of patients was distributed across five of the thirteen health states, in line 
with the patient distribution observed in the TargetCOPD trial for the 50 year old age-group, where 
52.7% were male (Table 1)12. 43.0% had no respiratory symptoms, 48.2% had symptoms but no airflow 
obstruction, and the remaining 8.8% were new COPD cases that were undiagnosed prior to participating 
in the trial. Among these newly-diagnosed patients, 69.0%, 27.4% and 3.6% had COPD GOLD stage 
1, 2 and 3 respectively. 
 Table 1: General model parameters related to case-finding processes 
 Parameter Value α β 
Starting cohort characteristics (percentage) 12 ¤     
Male 52.7 5999 5394 
Asymptomatic without COPD 43.0 364 482 
Symptomatic without COPD 48.2 364 482 
Undiagnosed COPD 8.8 74 772 
Proportion in GOLD stage 1 69.0 58 26 
Proportion in GOLD stage 2 27.4 23 61 
Proportion in GOLD stage 3 3.6 3 81 
Natural history of development of COPD (percentage per year)    
Development of symptoms24 25# 2.0 135 6775 
Incidence of COPD 26§¤ 0.6 55 9945 
Proportion of incident cases in GOLD stage 1 27‡ 72.2 44 17 
Proportion of incident cases in GOLD stage 2 27‡ 27.8 17 44 
Routine practice (percentage)12    
Probability of being diagnosed with COPD 0.8 337 41692 
Treatment after COPD diagnosis 29.3 3972 9585 
Systematic case-finding activities (percentage)12     
Received questionnaire 99.9 12175 1 
Responded to questionnaire 35.5 846 1572 
Reported symptom on questionnaire among responders 56.4 482 364 
Spirometry conducted in those  reporting symptoms 66.1 559 287 
Diagnosed with COPD in  those attending spirometry 39.8 87 2331 
Utility     
Asymptomatic without COPD15 0.8394 1522 291 
Symptomatic without COPD15 0.7549 8817 2862 
Costs (£)12  Value α λ 
Postal questionnaire 4.01 99 39 
Booking and conducting spirometry test 55.27 24 0.5 
‡  Cohort study of Danish general population at year 0, 5 and 15 (Copenhagen City Heart Study). Of symptomatic 
normal at baseline that later developed COPD 15 years later, 72% and 28% had GOLD stage 1 and 2 respectively. 
This was assumed to be a fixed distribution 
# Based on clinical opinion, it was considered that incident cases account for 10% of prevalent cases (20%) of 
respiratory symptoms in the UK population, which was validated using values from Eagan (2002). 
§ A longitudinal observational primary care database (Dutch Integrated Primary Care Information [IPCI]) follow-up 
study. The incidence rate was reported in 1000 person-years, which was then converted to one-year probability. 
¤ Age dependent parameters. Values presented are for 50-year-olds 
 Beta distribution: The symbols α and β are parameters that define a beta distribution, which is a continuous 
probability distribution bounded at the extremes by 0 and 1. The number of successes is α while failure is β. 
Gamma distribution: The symbols α and λ are parameters that define a gamma distribution, which is a continuous 
discrete distribution bounded at the extremes by 0 and ∞. The mean of the distribution is α(1/λ) and variance is  
α(1/λ)2 
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Transitions at every 3-month cycle were based on several assumptions to approximate the natural 
history and current management of COPD. Only patients who had developed symptoms could progress 
to any of the categories of undiagnosed COPD. Once a patient developed COPD, the model allowed 
movement to the immediate next worse GOLD stage. Direct deterioration beyond the next stage within 
a three-month period was not allowed because COPD was assumed to progress slowly (e.g. movements 
from GOLD 1 directly to 3 and from GOLD 2 to 4 were not allowed). Transition from an undiagnosed 
to a diagnosed health state was permitted, but not the reverse. Not all diagnosed patients received 
treatment (Figure 2). Improvements were only permitted in treated patients. Undiagnosed GOLD stage 
health states were assumed to have the same baseline transitions to worse undiagnosed GOLD stages 
as diagnosed health states. Finally, there was a risk of exacerbation and death in a 3-month time cycle 
within any health state. The case-finding processes were modelled as events within each health state 
(Figure 1). Systematic case-finding only occurred every three years, although a new diagnosis of COPD 
could arise through routine care in either strategy in every cycle. 
Data values used in the model 
Most of the data related to the process of case finding and diagnosis of COPD were derived from the 
active arm of the TargetCOPD trial12  and the associated Birmingham COPD cohort study15 (Table 1 
Table 2). Transition probabilities between GOLD stages were obtained from The Health Improvement 
Network (THIN) database, which holds longitudinal primary care information on over 11 million UK 
patients, including about 2 million with diagnosed COPD28 (See Supplementary material for detailed 
estimation methods). 
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Table 2: Model parameters related to disease progression and outcomes (per annum)  
  GOLD 1 GOLD 2 GOLD 3 
GOLD 
4 
Dead 
Transitions (probability)28 ¤      
GOLD 1 0.9047 0.0876 0.0000 0.0000 0.0077 
GOLD 2 0.0510 0.9001 0.0362 0.0000 0.0128 
GOLD 3 0.0000 0.1044 0.8368 0.0324 0.0265 
    GOLD 4 0.0000 0.0000 0.0936 0.8187 0.0877 
Transition for symptomatic patients¤      
Symptoms, no COPD26 27 0.0040 0.0015 0.0000 0.0000 0.0026** 
Exacerbation (probability)      
Severe exacerbation15* 0.0270 0.0760 0.2720 0.3480 - 
Mortality after severe exacerbation29 0.0703 0.0703 0.0703 0.0703 - 
Treatment effect (Odds ratio)       
All-cause mortality30 0.9800 0.9800 0.9800 0.9800 - 
Severe exacerbation30 0.8500 0.8500 0.8500 0.8500 - 
Progression to the next GOLD stage‡ 0.8500 0.8500 0.8500 0.8500 - 
Costs (£) †       
Scheduled GP and hospital visits19 164.56 267.06 394.01 541.06 - 
Inhaled medication29 485.16 567.84 735.96 824.52 - 
Inpatient stay due to exacerbation29 2263.00 2263.00 2263.00 2263.00 - 
Health outcomes           
Utility15* 0.7197 0.7013 0.6798 0.5855 - 
Disutility from severe exacerbation15* -0.2398 -0.2337 -0.2265 -0.1951 - 
Utility gained from treatment31 0.0367 0.0367 0.0367 0.0367 - 
† Cost method was adapted and unit costs were updated to 2015 price year. 
¤ Age depended parameters. Values presented are for 50-year-olds 
* Birmingham COPD cohort: Unpublished data from the Birmingham Lung Improvement StudieS – an ongoing 
series of studies aimed at evaluating better strategies for identifying and managing COPD in primary care. Disutility 
data shows utility loss over one year:50% utility loss in the first month and 25% utility loss for the second and third 
month per cycle. The impact of exacerbations on quality of life is greater in patients with less severe disease who 
also tend to be younger32.  
** Value represents mortality risk in the general population 
‡ Expert panel comprised consultant pulmonologists, epidemiologists and senior health economist. The panel was 
presented with results of prior scoping reviews on the effect of treatment on exacerbation, mortality and lung 
function, but there was no review transition between GOLD stages. Given that the odds ratio in reviews were 
around 0.85, the panel agreed then that the odds of treatment slowing disease progression to the next worse GOLD 
stage should be 0.85 for the base case. 
 
For pragmatic reasons, only severe exacerbations (i.e. those requiring in-patient stay33) were considered 
in this evaluation as these episodes alone account for over 84% of all COPD related healthcare costs34. 
The annual rate of severe exacerbations by undiagnosed and diagnosed GOLD stage was obtained from 
unpublished baseline data from the Birmingham cohort15. The rates were converted to quarterly 
transition probabilities and beta distributions were fitted about the point estimates.  
Age and sex specific all-cause mortality rates were obtained from the life tables for England and Wales35 
and applied to patients without COPD (Table S1). Rates were adjusted to avoid double counting COPD-
related mortality. Age specific all-cause mortality rates for diagnosed COPD patients were derived from 
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the annual transition matrix generated from the THIN database (Table S7). COPD-adjusted all-cause 
mortality for the “disease free” cohort was derived from the UK life tables (Table S1). 
Prescription patterns in UK primary care show 29.6% of COPD patients receive a LABA-based inhaled 
medication (excluding LAMA), 9.5% receive a LAMA-based combination (excluding LABA), and 
25.0% receive combinations that include LABA+LAMA36. Treatment effects from published 
systematic reviews suggest reductions in risk of exacerbations of up to 27% (OR=0.73) for some dual 
inhaler combinations with further reductions for triple drug combinations9. It was not practical to model 
treatment effects for each COPD inhaler combination on each type of outcome, therefore, a conservative 
simplifying assumption was made, using the point estimates from a meta-analysis of the effect of a 
single LAMA versus placebo on mortality (OR=0.98) and severe exacerbation (OR=0.85)30. The 
published evidence was largely based on patients with a forced expiratory volume in 1 second 
(FEV1)<60%, but the effect was assumed to be similar across all GOLD stages, although emerging 
evidence shows that patients with FEV1>60% may have even greater capacity to benefit from early 
treatment37.  
Only 29.3% of newly diagnosed patients were modelled to commence treatment annually36. This annual 
rate was derived from a study that showed 82.7% of COPD patients in the UK were on treatment 5 
years post diagnosis. This is likely to be a conservative estimate as reports from other countries suggest 
treatment initiation rates to be higher38.  
Utility values for undiagnosed and diagnosed GOLD stages 1 to 4 health states were derived from 
unpublished baseline data from the Birmingham cohort15, containing patients representative of a UK 
primary care COPD population in a stable condition and also symptomatic individuals without COPD. 
For individuals without symptoms; utility values were derived from a published age-adjusted algorithm, 
developed from utility values from the general population39, as there was no utility value for ever-
smokers in the general population in the literature. The model assumed that utility loss following severe 
exacerbation persisted for three months, in line with a previously published model29. Disutility was 
modelled to be higher in the first month (50%) compared to the second (25%) and third (25%) month, 
after which quality of life was assumed to return to pre-exacerbation levels. This loss was applied to 
mean utility scores across all the four COPD severity levels40 41.  
Resource use and costs: The cost of systematic case-finding was estimated from the active arm of the 
TargetCOPD trial12 (Table 1, Table 2 , Table S3, Table S4, Table S5). Estimation of healthcare costs 
for the diagnosed and treated GOLD stages (Table 2) followed existing costing frameworks29 41. Cost 
of COPD-related inhaled pharmacotherapy was calculated using data from diagnosed patients in the 
Birmingham cohort. No cost was attached to routine care or comorbidities since these were assumed to 
be the same for both arms.  
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Unit costs were primarily from the Personal Social Services Research Unit (PSSRU)42, NHS reference 
costs and the British National Formulary43. Costs were inflated to 2015 prices using the Hospital and 
Community Health Services (HCHS) inflation index42 where necessary. 
Assessment of cost-effectiveness 
An incremental cost-effectiveness ratio (ICER) was calculated as a ratio of the mean difference in cost 
and the mean difference in QALY gained between systematic case-finding and routine practice and 
presented as cost per QALY gained. Discounting was applied to costs and outcomes at a rate of 3.5% 
in line with NICE guidance16. Where available, data were entered into the model as distributions in 
order to fully incorporate the uncertainty around parameter values, so that a probabilistic sensitivity 
analysis could be undertaken. A gamma distribution was fitted for all cost parameters. A lognormal 
distribution, which accommodates the ratio nature of risk measures, was constructed for odds ratios. 
Beta distributions were fitted for all transition probabilities and utility estimates. The probabilistic 
sensitivity analysis was run with 10,000 simulations, and cost-effectiveness planes and cost-
effectiveness acceptability curves (CEAC) were produced. The CEAC is the standard method for 
quantifying the likelihood that an intervention is more cost-effect compared to an alternative.  
Additional one-way sensitivity analyses 
A series of one-way sensitivity analyses was conducted to assess how key parameters such as starting 
age of cohort, screening interval and time horizon affected the results. The impact of other important 
parameters such as questionnaire response rate, spirometry attendance rate, treatment initiation rates 
and the effectiveness of treatment with regards to exacerbations, mortality and quality of life gain were 
also explored. 
Results 
The base-case results for 50-year old ever smokers (Table 3) showed that compared to routine practice, 
a three-yearly systematic active case-finding strategy was more expensive but more effective, with a 
greater number of  QALYs gained over a lifetime time horizon. The difference in cost was £466, with 
0.0281 QALYs gained, producing an ICER of £16,596 per QALY gained. 
 
Table 3 Base-case result Cost-Utility Analysis 
Case-finding strategy Mean values Mean difference ICER 
  Cost (£) QALYs Cost (£) QALY (£/QALY) 
Routine care 1,007.64 14.1767    
Systematic case-finding 1,473.51 14.2048 465.87 0.0281 16,596.28 
Results from the probabilistic sensitivity analysis (Figure 3) showed all 10,000 resampled points were 
clustered in the North-East quadrant, representing instances where systematic case-finding was more 
expensive and more effective than routine practice. 78.4% of these points were below the 
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£20,000/QALY willingness-to-pay threshold (WTP)16, which represents the probability of systematic 
case-finding being cost-effective at that threshold.  The CEAC shows the probability of cost-
effectiveness at different WTP thresholds (Figure S1) 
 
Sensitivity analysis  
Varying the age for starting screening altered both the intervention costs and the QALYs gained (Table 
4). The most cost-effective age to begin screening in UK ever-smokers was estimated to be 60 years. 
Although the intervention costs were higher, the QALY gains from management of symptoms were 
also greater. Compared to younger age groups, a higher proportion of 60-year-olds had developed 
COPD during the first case-finding cycle, and therefore did not incur the costs associated with case-
finding in subsequent cycles. The 60-year-olds were also young enough to maximally benefit from 
treatment of their symptoms relative to older cohorts. 
Annual case-finding yielded the most benefit but was the most expensive strategy, whilst a screening 
interval of ten years had the lowest ICER thereby making the preferred screening interval from a cost-
effectiveness perspective. The sensitivity analysis results also showed that the minimum required 
screening questionnaire response rate was 12% for systematic case-finding to remain cost-effective at 
the £20,000 per QALY threshold. Similarly, systematic case-finding was only preferred to routine 
practice if more than 26% of those who were invited for spirometric confirmation attended the session.  
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 Table 4: Sensitivity analysis results 
  Cost difference 
QALY 
difference 
ICER (£/QALY) 
Cohort Age    
   40 years 356.32 0.0184 19,373.50 
   50 years 465.87 0.0281 16,596.28 
   60 years 520.27 0.0333 15,645.62 
   70 years 448.61 0.0265 16,915.53 
Screening Interval      
   1 year 910.08 0.0465 19,586.35 
   3 years 465.87 0.0281 16,596.28 
   5 years 334.09 0.0210 15,922.52 
   10 years 217.00 0.0143 15,219.88 
Time horizon    
   20 years 316.94 0.0147 21,522.47 
   30 years 411.87 0.0226 18,206.16 
   40 years 458.44 0.0272 16,883.96 
   50 years 465.87 0.0281 16,596.28 
Spirometry attendance rate    
   10.5%  (Threshold 2) 159.21 0.0054 29,556.13 
   26.3 % (Threshold 1) 260.33 0.0130 20,097.49 
   66.1%  (Base case) 465.87 0.0281 16,596.28 
Questionnaire response rate    
   4.0%  (Threshold 2) 122.88 0.0040 30,364.90 
  11.6% (Threshold 1) 219.19 0.0109 20,056.90 
   35.0% (Base case) 465.98 0.0281 16,595.80 
Utility gain from treatment    
   0.0000 465.87 0.0115 40,456.80 
   0.0092 (Threshold 2) 465.87 0.0155 30,011.41 
   0.0269 (Threshold 1) 465.87 0.0233 19,999.67 
   0.0367 (Base case) 465.87 0.0281 16,596.28 
Threshold 1= Willingness-to-pay threshold at £20,000 per QALY 
Threshold 2= Willingness-to-pay threshold at £30,000 per QALY 
Questionnaire response rate after the initial invite in the TargetCOPD trial = 15% (2312/15387)Error! Reference 
source not found. 
Questionnaire response rate after the first reminder in the TargetCOPD trial = 25% (3936/15387)Error! Reference 
source not found. 
Base case values are in bold fonts 
The model was also sensitive to the effectiveness of treatment on disease outcomes. The opportunity 
cost of systematic case-finding steadily increased as the effect of treatment worsened (Figure 4). Firstly, 
each variable was considered separately. When no impact on mortality was assumed, case-finding was 
still cost-effective at £17,663/QALY. No impact on exacerbations gave an ICER of £18,258/QALY. 
However, if no impact on progression (to worse GOLD stage) was assumed, the ICER rose to 
£22,943/QALY, and the threshold odds ratio for cost-effectiveness at £20,000/QALY was 0.94. When 
the odds ratios for the effectiveness of treatment on all outcomes were simultaneously adjusted to 1, 
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systematic case finding was not preferred over routine practice (Figure S2), with an ICER of 
£28,811/QALY.  
The model was also sensitive to the magnitude of the additional impact on quality of life which was 
independent of the impact on quality of life and survival from progression, mortality and exacerbation 
(Table 4). If the utility gain reduced to less than 0.0269, then systematic case finding was no longer 
cost-effective at £20,000/QALY. Assuming treatment had no additional impact on quality of life 
resulted in an ICER of £40,457/QALY. Another important determinant of cost-effectiveness was the 
treatment initiation rate. A systematic case-finding programme was cost-effective as long as treatment 
was initiated in at least 8% of previously untreated patients yearly (Figure 4). 
Discussion 
There are as yet no published primary studies which provide data on the long-term cost-effectiveness 
of a systematic programme of case finding for undiagnosed COPD.  In their absence, this novel 
economic model aims to address this unanswered question using data from the best published and 
unpublished sources available. We have shown that the systematic screening of ever-smokers aged 50 
years and over, every 3 years is potentially a cost-effective strategy according to UK cost-effectiveness 
thresholds. The results were supported by the majority of the sensitivity analyses except in the most 
extreme scenarios. For case-finding to be cost-effective, a sufficient proportion of patients must respond 
to the initial screening questionnaire (12%) and attend the confirmatory spirometry test (26%). In our 
published trial, 15% responded after the initial invite without a reminder12 and more than 63% of those 
invited attended the spirometry test. Crucially, one in twelve (8%) of previously untreated patients must 
also be started on treatment yearly for systematic case-finding to remain cost-effective. Unpublished 
data from long term follow up for the Target COPD trial suggests that twelve  months after diagnosis, 
21% of case-found patients in the active case-finding arm were on the practice COPD QOF register, 
suggesting they were likely to be receiving some treatment. Mean lifetime costs for both systematic 
case finding and routine care are relatively low (less than £1,500), however this can be explained by the 
low incidence of COPD and a relatively low proportion of undiagnosed COPD in the starting cohort. 
Therefore only a relatively small proportion of patients in the model will develop COPD over time and 
incur costs. Furthermore, in the case finding strategy, as approximately only a third of patients respond 
to the questionnaire, only a small proportion will actually go onto receive spirometry and incur these 
additional costs. 
We sought to explain why systematic case-finding was cost-effective despite the use of conservative 
assumptions, especially for treatment effectiveness. First, as our systematic case finding approach was 
relatively inexpensive, only a small proportion of newly diagnosed patients needed to benefit from 
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treatment for the intervention to be cost-effective. Second, once treatment commenced, the risk of 
exacerbation and mortality were simultaneously reduced. Fewer exacerbations result in lower loss in 
QALYs as well as cost savings from fewer admissions to hospital. Reduced risk of mortality among 
treated patients results in greater accumulation of QALYs compared to their untreated counterparts. 
Overall, mortality did not have a significant impact on the ICER because treated patients who survived 
longer also consumed more healthcare resources. There are also further benefits from the effect of 
treatment on disease progression, and we also assumed a small utility benefit of being on treatment 
independent of disease progression and exacerbations. If this additional benefit was removed, then case-
finding was no longer cost-effective.  
Ten yearly systematic active case-finding was the most cost-effective screening interval, although 
policymakers need to balance this against a greater proportion of the cohort remaining undiagnosed for 
longer and the value patients and practitioners place on early diagnosis44. 
To the best of our knowledge this is the first model to evaluate the long-term cost-effectiveness of a 
COPD case-finding strategy. The reliability of the main data sources that informed the model was a 
notable strength. Patient-level data from the TargetCOPD trial, the Birmingham COPD cohort, and 
THIN dataset provided up-to-date information on both diagnosed and undiagnosed COPD patients in 
primary care in the UK. 
Another strength was the use of conservative estimates of the treatment effect to prevent overestimation 
of the benefits of systematic case-finding. The natural history of COPD in untreated patients remains 
largely unknown. Here, we assumed that untreated and treated patients had the same natural history. In 
reality, undiagnosed patients may have a slightly poorer quality of life from sub-optimal management 
and the disease progression rate might be faster3 36.  
This study, however does have several limitations. The first limitation is the uncertainty around the 
effect of treatment on progression from one GOLD stage to the next45 46. This estimate was not available 
in the literature. Although some previous studies have shown that treatment slows lung function decline 
(for example changes in FEV1)47 48 <sup>2,3</sup>, there is currently no clear method for transforming 
changes in FEV1 decline into risk ratios that could be used in this model. Nonetheless, the reduced lung 
function decline in treated patients is an indication that treatment may reduce risk of progressing to a 
worse GOLD stage. However, in order to explore the uncertainty regarding the impact of treatment, 
extensive sensitive analyses were undertaken.  
Additionally, the treatment effect as used in this model only captured the benefits associated with 
inhaled medications. Other interventions such as smoking cessation which has been shown to be 
effective in reducing COPD progression49, pulmonary rehabilitation8 and self-management41 which 
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improve HRQoL and reduce exacerbations, were not considered. Inclusion of other interventions would 
have made systematic case-finding more cost-effective but few patients receive these interventions, 
thereby making their wider benefit uncertain.  
Another possible weakness is the use of the traditional GOLD staging criteria50 as airflow obstruction 
relates only weakly to quality of life. For instance, some patients with GOLD stage 2 may experience 
worse symptoms and impact than those with GOLD stage 3. Other symptom-based classification 
systems that are better predictors of prognosis now exist51. However there is no consensus regarding 
the most appropriate staging criteria and the GOLD staging used here was the one used in previous 
literature which has informed inputs for assumptions used in the model.  
We have also assumed that transitions between GOLD stages, exacerbation rates and utility values for 
undiagnosed states are the same as diagnosed (and untreated) GOLD stage health states. However, this 
assumption is supported by findings from cohort studies (e.g. the Can COLD study) that show that those 
with undiagnosed COPD have similar rates of health service use related to respiratory disease as those 
who have diagnosed COPD3.  
Despite this, a further weakness lies in the assumption made regarding costs of undiagnosed disease. 
Only COPD-related costs are taken into account rather than all-cause costs. This may underestimate 
costs in the undiagnosed states, where there may be greater health care utilisation (e.g. primary care 
visits) due to COPD but the costs are not yet related to the condition. We also assume that untreated 
patients do not incur any healthcare cost until an admission for severe exacerbation occurs, whereas it 
is likely that some would have received prescriptions for their symptoms. However, it would be difficult 
to estimate these additional health care costs, and the conservative approach we have taken means that 
it is likely that case-finding would be more cost-effective with their inclusion. 
A significant barrier to the implementation of case-finding programmes around the world has been the 
lack of evidence on whether the long term benefit of early diagnosis and treatment outweighs the 
associated cost. Our economic model suggests that systematic case finding leading to earlier diagnosis 
and treatment would provide benefits and value for money, despite uncertainty about treatment 
effectiveness in case-found patients and those with mild disease. The treatments would have to be 
almost completely ineffective on all important disease outcomes for regular case-finding to be a worse 
option than current practice. However, we recognise that this is not a primary study, and it would be 
strengthened by better knowledge about the natural history of the disease and treatment effectiveness. 
Ultimately, data from a case-finding trial with longer-term health outcomes would provide more robust 
evidence. We have also provided information on potential starting age and screening intervals. The 
exact configuration of such case-finding activity may however depend on local factors such as 
competing pressures on national budgets. A further need is to explore more fully patient views on earlier 
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diagnosis and the overall financial impact on primary healthcare organisations of a much larger 
population of COPD patients to manage. Should a new programme of case-finding be implemented, a 
clear pathway of care would need to be provided in order to ensure newly diagnosed patients are 
optimally treated, as current data suggest that this is seldom the case37.  
Conclusion 
We conclude that a three-yearly systematic approach to case-finding is likely to be cost-effective in the 
long term given the current management of COPD patients in primary care setting.  The true importance 
of early diagnosis and treatment of COPD will be better understood as more evidence emerges on the 
effect of treatment on COPD and the longer-term results of case-finding trials are available. Longer-
term follow-up of newly diagnosed patients may also further clarify the natural history of COPD. 
 
 
Figure legends 
 
Figure 1: Transitions between model health states 
 
Figure 2: Example of pathway for an undiagnosed patient with GOLD stage 3 during a 3-month 
systematic case-finding cycle 
 
Figure 3 Cost-effectiveness plane for the comparison of systematic case-finding with routine care, based 
on 10,000 cost-effect pairs 
 
Figure 4: Multiple one-way sensitivity analyses showing the relationship between ICER and (1)  the effect 
of treatment on exacerbation (2) the effect of treatment on Mortality (3) the effect of treatment on disease 
progression (4) the yearly treatment initiation rate in newly diagnosed patients. Treatment effectiveness 
estimates are expressed as odds ratios. 
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